ReviewExpert opinion on drug discovery2026
Leveraging machine learning for selective cannabinoid ligand discovery: methods, challenges, and opportunities.
Review in Expert opinion on drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From molecular mechanisms to digital surveillance: the 2010-2025 evolution of benzodiazepine and Z-drug misuse research.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionSelective modulation of cannabinoid receptors, particularly achieving CB2 selectivity over CB1, represents a promising strategy for developing safer therapeutics with reduced psychotropic effects. This review examines how machine learning (ML) approaches can address persistent challenges in cannabinoid receptors selectivity and accelerate drug discovery. AREAS COVERED: The authors summarize current ML-based methodologies applied to cannabinoid ligand discovery, focusing on strategies for predicting receptor affinity and selectivity. The literature covered was identified through a PubMed search followed by manual screening to retain studies directly relevant to cannabinoid-focused AI-driven ligand discovery. The review discusses feature engineering approaches, including molecular fingerprints, physicochemical descriptors, and SMILES-based representations, as well as classification and regression algorithms for selectivity prediction. The authors evaluate model performance metrics, dataset limitations, and interpretability challenges. Recent advances in deep learning and generative models for de novo molecular design are also highlighted, with emphasis on their potential to expand chemical space and improve selective ligand identification. EXPERT OPINION: ML has significantly advanced the prediction of cannabinoid receptor selectivity, yet progress remains constrained by data quality, endpoint inconsistency, and limited interpretability. Future efforts integrating curated datasets, mechanistically informed modeling, and generative AI frameworks are expected to substantially enhance the discovery of selective cannabinoid therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.